Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

417 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
Saito G, Oya Y, Taniguchi Y, Kawachi H, Daichi F, Matsumoto H, Iwasawa S, Suzuki H, Niitsu T, Miyauchi E, Yokoi T, Yokoyama T, Uenami T, Sakata Y, Arai D, Okada A, Nagata K, Teraoka S, Kokubo M. Saito G, et al. Among authors: teraoka s. Lung Cancer. 2021 Nov;161:86-93. doi: 10.1016/j.lungcan.2021.08.019. Epub 2021 Sep 5. Lung Cancer. 2021. PMID: 34543942
Analysis of advanced lung cancer patients diagnosed following emergency admission.
Fujimoto D, Shimizu R, Morimoto T, Kato R, Sato Y, Kogo M, Ito J, Teraoka S, Otoshi T, Nagata K, Nakagawa A, Otsuka K, Katakami N, Tomii K. Fujimoto D, et al. Among authors: teraoka s. Eur Respir J. 2015 Apr;45(4):1098-107. doi: 10.1183/09031936.00068114. Epub 2014 Oct 16. Eur Respir J. 2015. PMID: 25323241 Free article.
The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma.
Sato Y, Fujimoto D, Uehara K, Shimizu R, Ito J, Kogo M, Teraoka S, Kato R, Nagata K, Nakagawa A, Otsuka K, Hamakawa H, Takahashi Y, Imai Y, Tomii K. Sato Y, et al. Among authors: teraoka s. BMC Cancer. 2016 Nov 14;16(1):890. doi: 10.1186/s12885-016-2897-6. BMC Cancer. 2016. PMID: 27842505 Free PMC article.
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study.
Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, Imai Y, Ishida K, Fukuoka J, Tomii K. Teraoka S, et al. J Thorac Oncol. 2017 Dec;12(12):1798-1805. doi: 10.1016/j.jtho.2017.08.022. Epub 2017 Sep 20. J Thorac Oncol. 2017. PMID: 28939128 Free article.
Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.
Fujimoto D, Sato Y, Uehara K, Ishida K, Fukuoka J, Morimoto T, Kawachi H, Mori R, Ito M, Teraoka S, Nagata K, Nakagawa A, Otsuka K, Imai Y, Tomii K. Fujimoto D, et al. Among authors: teraoka s. J Thorac Oncol. 2018 Mar;13(3):377-386. doi: 10.1016/j.jtho.2017.11.123. Epub 2017 Dec 9. J Thorac Oncol. 2018. PMID: 29233789 Free article.
417 results